Subsidiary of Sailong Pharmaceutical Group (002898.SZ) receives approval notice for the listing application of chemical raw material drug acesolol hydrochloride

Sailong Pharmaceutical Group (002898.SZ) announced that its wholly-owned subsidiary, Hunan Sailong Pharmaceutical Group Co., Ltd., recently received approval from the National Medical Products Administration for the issuance of the approval notification for the listing application of Atenolol hydrochloride as a chemical raw material. Atenolol hydrochloride formulations are mainly used for the treatment of paroxysmal supraventricular tachycardia or non-compensatory sinus tachycardia, intraoperative and postoperative tachycardia, and/or hypertension.